NuCana PLCNASDAQ:NCNANASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE3.8400
- TODAY'S CHANGE (%)-0.1600 (-4.0000%)
- Bid / Lots3.7600/ 2
- Ask / Lots4.2900/ 3
- Open / Previous Close4.0100 / 4.0000
- Day Range
- 52 Week Range
- Volume12,017
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | NCNA |
|---|---|---|
| 09:32 ET | 588 | 4.01 |
| 09:36 ET | 605 | 4.08 |
| 09:41 ET | 200 | 4.09 |
| 09:45 ET | 264 | 4.02 |
| 09:57 ET | 164 | 4.01 |
| 10:19 ET | 610 | 3.89 |
| 10:46 ET | 195 | 3.91 |
| 10:51 ET | 1517 | 3.94 |
| 10:55 ET | 198 | 3.9072 |
| 11:22 ET | 174 | 3.91 |
| 11:29 ET | 300 | 3.9 |
| 12:36 ET | 220 | 3.872 |
| 12:54 ET | 200 | 3.93 |
| 02:02 ET | 400 | 3.83 |
| 02:49 ET | 100 | 3.8 |
| 02:56 ET | 238 | 3.75 |
| 02:58 ET | 165 | 3.815 |
| 03:14 ET | 2961 | 3.86 |
| 03:45 ET | 600 | 3.84 |
| 03:54 ET | 100 | 3.84 |
Apr 9, 2024
Apr 1, 2024
DJ NuCana Price Target Maintained With a $4.00/Share by Oppenheimer, from 9:34AM ET on Monday Apr 01, 2024 by Dow Jones
9:34AM ET on Monday Apr 01, 2024 by Dow Jones
Mar 27, 2024
DJ NuCana American Depositary Shares Fall on News of Planned Ratio Change, from 5:14PM ET on Wednesday Mar 27, 2024 by Dow Jones
5:14PM ET on Wednesday Mar 27, 2024 by Dow Jones*DJ NuCana: Announces Plan to Implement ADS Ratio Change, from 4:34PM ET on Wednesday Mar 27, 2024 by Dow Jones
4:34PM ET on Wednesday Mar 27, 2024 by Dow JonesNuCana Announces Plan to Implement ADS Ratio Change, from 4:30PM ET on Wednesday Mar 27, 2024 by Dow Jones
4:30PM ET on Wednesday Mar 27, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
NuCana PLC | 8.5M | 0.0x | --- |
National Graphite Corp | 10.5M | -3.1x | --- |
Cell MedX Corp | 10.4M | -14.8x | --- |
Galera Therapeutics Inc | 10.6M | -0.1x | --- |
Aslan Pharmaceuticals Ltd | 10.6M | -0.2x | --- |
Moleculin Biotech Inc | 10.2M | -0.3x | --- |
Company Information
NuCana plc is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is focused on developing treatment outcomes for patients with cancer by applying its ProTide technology. The Company's pipeline includes NUC-3373, and NUC-7738. NUC-3373 is a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil (5-FU). 5-FU is a prescribed anti-cancer agent. NUC-3373 has been evaluated in a Phase I clinical trial for patients with advanced solid tumors and is under Phase Ib/II clinical trial for patients with advanced colorectal cancer. NUC-7738 is a ProTide transformation of a nucleoside analog, 3’-deoxyadenosine (3’-Da). The Company is evaluating NUC-7738 in a Phase I/II clinical trial for patients with advanced solid tumors. Its pipeline also includes Acelari, which is a ProTide transformation of the nucleoside analog gemcitabine. The Company’s subsidiaries include NuCana, Inc., NuCana Limited and NuCana BioMed Trustee Company Limited.
Contact Information
- Headquarters
- Lochside House, 3 Lochside WayEDINBURGH, United Kingdom EH12 9DT
- Phone
- 131-248-3660
- Fax
- 131-248-3001
Executives
- Non-Executive Independent Chairman of the Board
- Andrew Kay
- Chief Executive Officer, Co-Founder, Executive Director
- Hugh Griffith
- Chief Financial Officer
- Donald Munoz
- Chief Medical Officer
- Jeffrey Bloss
- Head - Translational Studies
- David Harrison
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $8.5M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 84.6K |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.03 |
EPS | $-408.84 |
Book Value | $8.76 |
P/E Ratio | 0.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
